Serum Vascular Endothelial Growth Factor as a Possible Prognostic Indicator in Sarcoidosis
Authors:
- 1 October 2003
- journal article
- research article
- Published by Springer Nature in Lung
- Vol. 181 (5) , 259-265
Abstract
Sarcoidosis is a systemic granulomatous disorder of unknown etiology, which involves the lung, eye, liver, and other organs. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis involved in an important role in the development of granuloma. However, only a limited number of studies have reported on the relationship between serum VEGF values and the clinical status of sarcoidosis. Concentrations of serum VEGF were determined in 33 patients with sarcoidosis. We investigated the correlation between serum VEGF values and extent of disease, prognosis, and radiographic stage compared with serum angiotensin converting enzyme (ACE) values as another candidate. Concentrations of serum VEGF in patients who received corticosteroid treatment were significantly higher than those of patients with spontaneous remission (p < 0.05). In addition, serum VEGF values in patients with extrathoracic involvements were significantly higher than those of patients with sarcoid lesions limited to the thoracic space (p < 0.05), accompanied by a tendency to increase the number of organs involved. The values of serum ACE revealed no relationship to the values of serum VEGF, administration of corticosteroid, or extrathoracic involvements. We concluded that serum VEGF values in patients with sarcoidosis is a predictive factor in determining extrathoracic organ involvements and as a parameter for deciding the necessity of treatment with corticosteroid. Serum VEGF might be a useful marker as a prognostic indicator in sarcoidosis.Keywords
This publication has 18 references indexed in Scilit:
- Significance of Vascular Endothelial Cell Growth Factor Up-Regulation Mediated via a Chymase-Angiotensin-Dependent Pathway during Angiogenesis in Hamster Sponge GranulomasThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Sarcoidosis: clinical update.2001
- The Gene Polymorphism of Tumor Necrosis Factor-β, But Not That of Tumor Necrosis Factor-α, Is Associated With the Prognosis of SarcoidosisChest, 2001
- Increased Serum Level of Vascular Endothelial Growth Factor in Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2000
- CC Chemokine Receptor Gene Polymorphisms in Czech Patients with Pulmonary SarcoidosisAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung diseaseJournal of Laboratory and Clinical Medicine, 2000
- Increased Expression of Vascular Endothelial Growth Factor in Pyogenic GranulomasActa Dermato-Venereologica, 1999
- Clinical courses and prognoses of pulmonary sarcoidosisCurrent Opinion in Pulmonary Medicine, 1999
- ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders.1999
- The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patientsEuropean Respiratory Journal, 1999